United Therapeutics Corporation (UTHR)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $25.04B
Last updated: Nov 17, 2026 at 4:33 PM ET
United Therapeutics Corporation (UTHR) Statistics
United Therapeutics (UTHR) has a market cap of $25.04B and an enterprise value of $23.85B. Its trailing P/E of 22.0x is above its 10-year median of 12.4x. It kept 38.61% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 4.75% below the market cap, as cash exceeds debt.
| Market Cap | $25.04B |
|---|---|
| Enterprise Value | $23.85B |
| Latest price (Nov 17, 2026) | $584.10 |
Key Dates
The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 7.8x and 4.0x. Its year-end P/E ranged from 8.9x to 17.5x from 2016 to 2025.
| P/E Ratio | 22.0x |
|---|---|
| Forward P/E | 21.8x |
| P/S Ratio | 7.8x |
| Forward P/S | 7.7x |
| P/B Ratio | 4.0x |
| P/TBV Ratio | 4.0x |
| P/FCF Ratio | 28.8x |
| P/OCF Ratio | 17.5x |
| PEG Ratio | 1.6 |
Enterprise Valuation
Counting debt and cash, the company is valued at 16.2x EBITDA and 27.4x free cash flow.
| EV / Earnings | 19.4x |
|---|---|
| EV / Sales | 7.5x |
| EV / EBITDA | 16.2x |
| EV / FCF | 27.4x |
Price Statistics
The stock is up 25.24% over 52 weeks and trades 6.91% above its 50-day average.
| Beta (1Y) | 0.43 |
|---|---|
| 52-Week Change | +25.24% |
| 1-Month Change | +7.54% |
| 3-Month Change | +10.39% |
| 6-Month Change | +3.05% |
| 5-Year Change | +213.86% |
| 10-Year Change | +398.64% |
| Total Return (1Y) | +25.24% |
| Total Return (3Y CAGR) | +36.63% |
| Total Return (5Y CAGR) | +23.60% |
| Return vs SPY (1Y) | +11.00% |
| Max Drawdown (1Y) | -20.87% |
| Max Drawdown (3Y) | -33.00% |
| Sharpe Ratio (1Y) | 0.60 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $546.33 |
| 200-Day Average | $538.59 |
| 52-Week Range | $455.63 to $614.23 |
| RSI (14 Days) | 54.5 |
| Average Volume (20 Days) | 522.66K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.61x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 4.61x |
|---|---|
| Quick Ratio | 4.29x |
| Debt / Equity | 0.00x |
| Interest Coverage | 115.08x |
Returns and Efficiency
Return on equity is 19.61% over the last 12 months, against a 5-year average of 16.20%.
| Return on Equity (ROE) | 19.61% |
|---|---|
| Return on Assets (ROA) | 17.50% |
| ROE (5Y Average) | 16.20% |
| ROA (5Y Average) | 13.63% |
| ROIC (5Y Average) | 14.42% |
| Asset Turnover | 0.44x |
| Inventory Turnover | 2.20x |
| Receivables Turnover | 9.68x |
| Cash Conversion Cycle | -223 days |
Taxes
Income tax took 18.37% of pretax income over the last 12 months.
| Income Tax (TTM) | $277.00M |
|---|---|
| Effective Tax Rate | 18.37% |
Scores
UTHR has an Altman Z-Score of 23.10, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 23.10 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $3.19B over the last 12 months is up 1.89% from the 12 months before.
| Revenue | $3.19B |
|---|---|
| Revenue Growth (YoY) | +1.89% |
| Gross Profit | $2.75B |
| Operating Income | $1.32B |
| Pretax Income | $1.51B |
| Net Income | $1.23B |
| Reported EPS (TTM) | $26.50 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 89.33% of the $7.03B in total assets.
| Cash and Equivalents | $1.19B |
|---|---|
| Total Debt | $0 |
| Net Cash | $1.19B |
| Net Cash Per Share | $27.84 |
| Working Capital | $2.26B |
| Shareholder Equity | $6.28B |
| Book Value Per Share | $146.98 |
| Tangible Book Value | $6.16B |
| Tangible Book Per Share | $144.30 |
| Total Assets | $7.03B |
| Total Liabilities | $758.10M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $562.40M of capital spending, operating cash flow left $867.20M of free cash flow.
| Operating Cash Flow | $1.43B |
|---|---|
| Capital Expenditures | $562.40M |
| Free Cash Flow | $867.20M |
| FCF Per Share | $20.22 |
| Depreciation and Amortization | $96.00M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 41.45%, against a 5-year average of 45.85%.
| Gross Margin | 86.34% |
|---|---|
| Operating Margin | 41.45% |
| Pretax Margin | 47.30% |
| Net Margin | 38.61% |
| FCF Margin | 27.21% |
| Gross Margin (5Y Average) | 90.20% |
| Operating Margin (5Y Average) | 45.85% |
| Net Margin (5Y Average) | 38.31% |
Growth
Revenue grew 18.02% a year over 3 years, and EPS 20.19% a year.
| Revenue Growth (3Y CAGR) | +18.02% |
|---|---|
| Revenue Growth (5Y CAGR) | +16.50% |
| EPS Growth (3Y CAGR) | +20.19% |
| EPS Growth (5Y CAGR) | +15.87% |
| FCF Growth (3Y CAGR) | +16.18% |
| FCF Growth (5Y CAGR) | +8.37% |
| Operating Income Growth (3Y CAGR) | +15.06% |
| Book Value Per Share Growth (2Y CAGR) | +11.03% |
| Tangible Book Per Share Growth (2Y CAGR) | +11.18% |
Dividends and Yields
UTHR does not pay a dividend. Its free cash flow yield is 3.48%.
| Earnings Yield | 4.55% |
|---|---|
| FCF Yield | 3.48% |
| Buyback Yield | 7.98% |
| Shareholder Yield | 7.98% |
Stock Splits
The last split was a 2-for-1 forward split on Sep 23, 2009.
| Last Split Date | Sep 23, 2009 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 9 similar companies, UTHR has the 4th highest P/E.
P/E RatioPeer median 18.5x
P/S RatioPeer median 2.9x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +5.73%
| P/E Ratio | 22.0x vs 18.5x median |
|---|---|
| P/S Ratio | 7.8x vs 2.9x median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +1.89% vs +5.73% median |
Analyst Forecast
Consensus estimates put revenue growth at 6.41% and EPS growth at 6.16% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +6.41% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +6.16% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About UTHR
What is UTHR's market cap?
United Therapeutics has a market cap of $25.04B. Its enterprise value, which adds debt and subtracts cash, is $23.85B.
What is UTHR's P/E ratio?
United Therapeutics has a trailing P/E ratio of 22.0x and a forward P/E of 21.8x.
How many shares of UTHR are outstanding?
United Therapeutics has 42.70M shares outstanding. The count is down 2.51% from a year earlier.
Does UTHR pay a dividend?
No. United Therapeutics does not pay a dividend.
How much debt does UTHR have?
United Therapeutics has $0 of total debt and $1.19B of cash and equivalents, a net cash position of $1.19B.
UTHR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts